In vitro study of the effect of photodynamic therapy on pituitary adenomas

Marks, Paul; Buxton, Timothy; Furneaux, Christopher E.

doi:10.3109/02688699309103495

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential use of PDT for the treatment of native pituitary adenomas (PAs) presents a very intriguing option as complete resection of these tumors is often unachievable. Pre-clinical studies of first-generation PS-guided PDT in PAs reported successful cytotoxicity and anti-tumor effect in both in vitro and mouse models [209,210]. Currently, clinical studies on PDT use for PAs have used first-generation PSs for therapy.…”

Section: Pdt In Other Cns Tumorsmentioning

confidence: 99%

Systematic Review of Photodynamic Therapy in Gliomas

Hsia

Small

Yekula

et al. 2023

Cancers

View full text Add to dashboard Cite

Over the last 20 years, gliomas have made up over 89% of malignant CNS tumor cases in the American population (NIH SEER). Within this, glioblastoma is the most common subtype, comprising 57% of all glioma cases. Being highly aggressive, this deadly disease is known for its high genetic and phenotypic heterogeneity, rendering a complicated disease course. The current standard of care consists of maximally safe tumor resection concurrent with chemoradiotherapy. However, despite advances in technology and therapeutic modalities, rates of disease recurrence are still high and survivability remains low. Given the delicate nature of the tumor location, remaining margins following resection often initiate disease recurrence. Photodynamic therapy (PDT) is a therapeutic modality that, following the administration of a non-toxic photosensitizer, induces tumor-specific anti-cancer effects after localized, wavelength-specific illumination. Its effect against malignant glioma has been studied extensively over the last 30 years, in pre-clinical and clinical trials. Here, we provide a comprehensive review of the three generations of photosensitizers alongside their mechanisms of action, limitations, and future directions.

show abstract

Section: Pdt In Other Cns Tumorsmentioning

confidence: 99%

Systematic Review of Photodynamic Therapy in Gliomas

Hsia

Small

Yekula

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In the preclinical studies, we have been able to show that PDT is active both in vitro, 21 as well as in vivo against a whole variety of histological subtypes of pituitary adenomas. 2 2 The results of our laboratory studies prompted us to develop a clinical protocol to treat patients whose pituitary adenomas recurred despite surgery and radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial ‘ an early report

Marks

Belchetz

Saxena

et al. 2000

British Journal of Neurosurgery

View full text Add to dashboard Cite

Pituitary adenomas, although histologically benign, are not always curable by surgery alone, principally because of dural infiltration, as well as their peculiar anatomical location. Radiotherapy has been employed as an adjuvant therapy to address residual disease with favourable results. This approach is, however, not without side effects, and it cannot be repeated. We are therefore investigating the effectiveness of photodynamic therapy (PDT) on recurrent pituitary adenomas in humans. This study details the protocol applied to 12 patients with recurrent pituitary adenomas, which involved systemic administration of photosensitizer (Photofrin) followed, after a period of 24-48 h, by intraoperative illumination of the tumour bed using 630 nm laser light. The primary end points were visual, endocrine and radiological improvement. The incidence of side effects was also monitored. The longest follow-up is 2 years. Most patients suffering from visual acuity or field defects have shown improvement when followed for 12 months or more. Three patients showed complete recovery of their visual fields. All those who presented with functional adenomas have shown reduction in their hormone levels. Tumour volume, relative to the preoperative size, was 122, 87, 66, 60 and 46% at 4 days, and 3, 6, 18 and 24 months, respectively. One patient developed severe skin photosensitization due to early exposure to direct sunlight and three others displayed minor skin reactions. There was no treatment-related mortality or morbidity. One patient (operated transcranially) developed hemiparesis postoperatively, which recovered completely. We think this is unrelated to the treatment. This prospective study demonstrates that PDT may be safely applied to the pituitary fossa by the trans-sphenoidal route and indicates the need for a randomized, controlled trial in order to establish its therapeutic potential.

show abstract